



Name	Byong Duk Ye
Affiliation	Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine
Country	Republic of Korea
Major Field	Inflammatory bowel disease

Educational Background

1991–1993: Pre-medical course, College of Natural Science, Seoul National University, Seoul, Korea
 1993–1997: College of Medicine, Seoul National University, Seoul, Korea
 2002–2005: Graduate School of Public Health (Master degree), Seoul National University, Seoul, Korea
 2005–2007: Graduate School of Medicine (PhD degree), Seoul National University, Seoul, Korea

Professional Experience

Sep 2021–Present: Director, Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
 Mar 2007–Present: Professor, Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
 Feb 2014–Jan 2016: Visiting Scholar, Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA
 Jan 2023–Present: Associate editor, Inflammatory Bowel Diseases
 Jan 2025–Present: Deputy editor, Journal of Gastroenterology and Hepatology
 Apr 2025–Present: Secretary General, Korean Association for the Study of Intestinal Diseases (KASID)
 Nov 2023–Nov 2025: Director, Scientific Board, Korean Society of Gastroenterology
 Apr 2023–Apr 2025: Treasurer, Korean Association for the Study of Intestinal Diseases (KASID)
 Apr 2021–Apr 2023: Director, Scientific Committee, Korean Association for the Study of Intestinal Diseases (KASID)
 Apr 2019–Apr 2021: Director, International Academic Exchange Committee, Korean Association for the Study of Intestinal Diseases (KASID)

Main Scientific Publications

1. Kim K, Yoon AR, Oh K, et al. Association of early vedolizumab trough levels with clinical, biochemical, endoscopic response and drug optimization during maintenance therapy in patients with inflammatory bowel diseases. *Sci Rep.* 2026 Feb 16. doi: 10.1038/s41598-026-39413-7 (Corresponding author).
2. Lee CK, Moon W, Chun J, et al. One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn's Disease: The K-STAR Study. *Inflamm Bowel Dis* 2025;31:1306–1316 (Corresponding author).
3. Lee HS, Lee Y, Baek J, et al. Nonlesional ileal transcriptome in Crohn's disease reveals alterations in immune response and metabolic pathway. *J Gastroenterol Hepatol* 2025;40:208–217 (Corresponding author).
4. Seo J, Kim S, Hong SW, et al. Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study. *Aliment Pharmacol Ther* 2024;60:389–400 (Corresponding author).
5. Kim K, Park JJ, Yoon H, et al. Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study. *Aliment Pharmacol Ther* 2024;59:1539–1550 (Corresponding author).
6. Lee Y, Baek J, Park S, et al. Characterization of Th17 tissue-resident memory cells in non-inflamed

SIDDS 2026

Navigating Towards the Optimum Digestive Care : Beyond Linguistic Barriers



Date Apr. 18.(Sat)-19.(Sun) 2026

Venue Grand Walkerhill Seoul, Korea



- intestinal tissue of Crohn's disease patients. *J Autoimmun* 2024;145:103206 (Corresponding author).
7. Kim K, Park S, Lee Y, et al. Transcriptomic Profiling and Cellular Composition of Creeping Fat in Crohn's disease. *J Crohns Colitis* 2024;18:223–232 (Corresponding author).
8. Seo M, Kim Y, Ye BD, et al. Positron emission tomography imaging of system xc- in immune cells for assessment of disease activity in mice and patients with inflammatory bowel disease. *J Nucl Med* 2022;63:1586–1591 (Co-first author).
9. Jung S, Ye BD, Lee HS, et al. Identification of Three Novel Susceptibility Loci for Inflammatory Bowel Disease in Koreans in an Extended Genome-Wide Association Study. *J Crohns Colitis* 2021;15:1898–1907 (Co-first author).
10. Schreiber S, Ben-Horin S, Jaroslaw Leszczyszyn J, et al. Randomized Controlled Trial: Subcutaneous versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. *Gastroenterology* 2021;160:2340–2353 (Corresponding author).